Transitional dynamics in oncology clinical trials: evaluating the impact of Clinical Trials Act on cooperative groups
CONCLUSION: the number of multicentre clinical trials in oncology gradually decreased after the Clinical Trials Act's enforcement, which underscores the need for comprehensive amendment of the Clinical Trials Act to streamline the operational process.PMID:38535873 | DOI:10.1093/jjco/hyae034 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Kenichi Nakamura Koji Takeda Akiko M Saito Miho Kato Shinya Sato Satoshi Nakagawa Yasuyuki Kawamoto Eiji Oki Isamu Okamoto Hiroaki Okamoto Hiroshi Katayama Junki Mizusawa Harumi Kaba Taro Shibata Haruhiko Fukuda Source Type: research
Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?
CONCLUSIONS: Locally advanced ESCC patients with time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery > 8 weeks were associated with worse long-term survival.PMID:38536527 | DOI:10.1007/s00432-024-05696-4 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Jiacong Liu Linhai Zhu Xuhua Huang Zhongjie Lu Yanye Wang Yuhong Yang Jiayue Ye Chen Gu Wang Lv Chong Zhang Jian Hu Source Type: research
Toward Racial Equity in Lung Cancer Screening Eligibility
J Clin Oncol. 2024 Mar 27:JCO2400351. doi: 10.1200/JCO.24.00351. Online ahead of print.NO ABSTRACTPMID:38537157 | DOI:10.1200/JCO.24.00351 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Hasmeena Kathuria Renda Soylemez Wiener Source Type: research
Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022
CONCLUSION: The ASCO/FoCR/FDA task force recommendations were associated with a shift in patterns of brain metastases exclusion criteria from conditionally excluded to not excluded. These findings demonstrate that the cancer clinical trial community has begun to change the way trials are written to be more inclusive.PMID:38537158 | DOI:10.1200/JCO.23.01777 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Hong Xiao Riha Vaidya Dawn L Hershman Joseph M Unger Source Type: research
Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility
CONCLUSION: Use of a 20-year smoking duration cutoff instead of a 20-pack-year cutoff greatly increases the proportion of patients with lung cancer who would qualify for screening and eliminates the racial disparity in screening eligibility between Black versus White individuals; smoking duration has the added benefit of being easier to calculate and being a more precise assessment of smoking exposure compared with pack-year smoking history.PMID:38537159 | DOI:10.1200/JCO.23.01780 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Alexandra L Potter Nuo N Xu Priyanka Senthil Deepti Srinivasan Hang Lee G Scott Gazelle Lydia Chelala Wei Zheng Florian J Fintelmann Lecia V Sequist Jessica Donington Julie R Palmer Chi-Fu Jeffrey Yang Source Type: research
Correction: A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle
J Exp Clin Cancer Res. 2024 Mar 26;43(1):93. doi: 10.1186/s13046-024-03018-7.NO ABSTRACTPMID:38532446 | DOI:10.1186/s13046-024-03018-7 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Bolin Wang Jinli Pei Shengnan Xu Jie Liu Jinming Yu Source Type: research
Transitional dynamics in oncology clinical trials: evaluating the impact of Clinical Trials Act on cooperative groups
CONCLUSION: the number of multicentre clinical trials in oncology gradually decreased after the Clinical Trials Act's enforcement, which underscores the need for comprehensive amendment of the Clinical Trials Act to streamline the operational process.PMID:38535873 | DOI:10.1093/jjco/hyae034 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Kenichi Nakamura Koji Takeda Akiko M Saito Miho Kato Shinya Sato Satoshi Nakagawa Yasuyuki Kawamoto Eiji Oki Isamu Okamoto Hiroaki Okamoto Hiroshi Katayama Junki Mizusawa Harumi Kaba Taro Shibata Haruhiko Fukuda Source Type: research
Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?
CONCLUSIONS: Locally advanced ESCC patients with time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery > 8 weeks were associated with worse long-term survival.PMID:38536527 | DOI:10.1007/s00432-024-05696-4 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Jiacong Liu Linhai Zhu Xuhua Huang Zhongjie Lu Yanye Wang Yuhong Yang Jiayue Ye Chen Gu Wang Lv Chong Zhang Jian Hu Source Type: research
Toward Racial Equity in Lung Cancer Screening Eligibility
J Clin Oncol. 2024 Mar 27:JCO2400351. doi: 10.1200/JCO.24.00351. Online ahead of print.NO ABSTRACTPMID:38537157 | DOI:10.1200/JCO.24.00351 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Hasmeena Kathuria Renda Soylemez Wiener Source Type: research
Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022
CONCLUSION: The ASCO/FoCR/FDA task force recommendations were associated with a shift in patterns of brain metastases exclusion criteria from conditionally excluded to not excluded. These findings demonstrate that the cancer clinical trial community has begun to change the way trials are written to be more inclusive.PMID:38537158 | DOI:10.1200/JCO.23.01777 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Hong Xiao Riha Vaidya Dawn L Hershman Joseph M Unger Source Type: research
Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility
CONCLUSION: Use of a 20-year smoking duration cutoff instead of a 20-pack-year cutoff greatly increases the proportion of patients with lung cancer who would qualify for screening and eliminates the racial disparity in screening eligibility between Black versus White individuals; smoking duration has the added benefit of being easier to calculate and being a more precise assessment of smoking exposure compared with pack-year smoking history.PMID:38537159 | DOI:10.1200/JCO.23.01780 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Alexandra L Potter Nuo N Xu Priyanka Senthil Deepti Srinivasan Hang Lee G Scott Gazelle Lydia Chelala Wei Zheng Florian J Fintelmann Lecia V Sequist Jessica Donington Julie R Palmer Chi-Fu Jeffrey Yang Source Type: research
Radiological and clinical features of large consolidative-type pulmonary invasive mucinous adenocarcinoma
CONCLUSION: Halo, vacuole, angiogram, and dead branch signs were frequently observed in consolidative-type IMA. Kirsten rat sarcoma viral oncogene mutations are common in consolidative-type IMA, especially site G12V, whereas epidermal growth factor receptor mutations were rare; therefore, gene immunotherapy was more difficult. Most patients were in stage T3-T4; however, lymph node metastasis was rare.PMID:38529681 | PMC:PMC10964172 | DOI:10.1111/crj.13743 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Jiaqi Chen Linlin Qi Jianwei Wang Liyan Xue Qi Xue Jia Jia Guochao Zhang Jianing Liu Fenglan Li Shulei Cui Source Type: research
Metastasis ability, genomic profile, subtype characteristic and curative efficacy of multiple pulmonary hematogenous metastases in lung cancer
Clin Transl Med. 2024 Mar;14(3):e1639. doi: 10.1002/ctm2.1639.NO ABSTRACTPMID:38530159 | PMC:PMC10964915 | DOI:10.1002/ctm2.1639 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Liuer He Xin Nie Jiayi Gao Yue Yuan Xue Wang Xu Li Fengzhu Guo Min Tang Ping Zhang Lin Li Source Type: research
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
CONCLUSIONS: Consensus clinical suggestions were generated on the most relevant scenarios such as diagnosis, staging and treatment of locally advanced lung cancer, which will serve to support decision-making in daily practice.PMID:38530556 | DOI:10.1007/s12094-024-03382-y (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Aylen Vanessa Ospina Sergio Bolufer Nadal Jos é Luis Campo-Cañaveral de la Cruz Jose Luis Gonz ález Larriba Ivan Mac ía Vidueira Bartomeu Massut í Sureda Ernest Nadal Florentino Hernando Trancho Antonio Álvarez Kindelán Edel Del Barco Morillo Reyes Source Type: research
Immune Checkpoint Inhibitor-Associated Systemic Sclerosis in the Treatment of a Small Cell Lung Cancer Patient with Durvalumab: A Case Report
Clin Cosmet Investig Dermatol. 2024 Mar 18;17:663-669. doi: 10.2147/CCID.S451386. eCollection 2024.ABSTRACTAs one of the key cancer treatment measures, immune-checkpoint inhibitors (ICIs) have revolutionized the treatment landscape of various cancers, including malignancies previously thought to be untreatable. Immune checkpoint inhibitors work by targeting the dysfunctional immune system, to enhance cancer-cell killing by CD8-positive T cells. Despite the beneficial effects of ICIs, these treatments are also linked to a novel class of side effects, termed immune-related adverse events (irAEs). Immune-related adverse event...
Source: Clinical Lung Cancer - March 25, 2024 Category: Cancer & Oncology Authors: De-Hu Li Xian-Zhi Xiong Source Type: research
